Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

World Video | Defence | Foreign Affairs | Natural Events | Trade | NZ in World News | NZ National News Video | NZ Regional News | Search

 

Truscreen Selected For Major Chinese Screening Programme

Truscreen Selected For Major Chinese Screening Programme

Cancer technology company TruScreen Limited (NZAX: TRU) advises that its technology has been selected for use in a major cervical cancer screening programme in North China.

The public screening programme is expected to screen 160,000 women over the next 18 months and is being funded by the Harbin Division of the All China Federation of Trade Unions (“ACFTU”). The programme is being conducted under the control of the Provincial Cancer Hospital of Heilongjiang, located in Harbin City, and involves a number of other leading hospitals in the Province. TruScreen has satisfactorily completed all medical device accreditation and verification requirements and completed training of all medical teams involved.

CEO of TruScreen, Mr Martin Dillon, said: “Providing our technology for use in fully funded public screening campaigns for cervical cancer in the enormous Chinese market is an important part of our strategy. ACFTU is the largest trade union in the world with over 280 million members, and we are delighted to be affiliated with this programme. We hope to leverage off this association and extend the use of the TruScreen technology to similar programmes in other provinces throughout China”.

The TruScreen system was selected due to a combination of its real time nature and its high ability to identify disease, alongside its portability and independence from laboratory infrastructure. This is different to other available screening methods and enables the speedy implementation of a large population based screening program.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

TruScreen is the only real time device in the world that is CE certified for the stand-alone primary screening of cervical cancer. It successfully combines the use of both optical and electrical tissue differentiation to create a clinically acceptable level of performance as a primary screening tool.

TruScreen to Announce FY16 Results on 13 June 2016; Approval to remain on NZAX Platform

TruScreen advises that it expects to announce its full year results for the year ended 31 March 2016, by 14 June 2016. In addition, the company has confirmed that it has received notice that it will not need to migrate its listing to the NXT Market platform operated by NZX Limited during the next 12 months.

ENDS

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
World Headlines

 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.